FDA Explores Reserving Brand Names At Phase II To Reduce “Trade Wrecks”
Executive Summary
FDA is exploring the possibility of allowing companies to reserve trade names at the end of Phase II in an effort to provide more certainty for firms building a marketing campaign around a brand
You may also be interested in...
Drug Name Battles May Be Waged More Publicly; FDA Petitioned On Zentase
FDA's efforts to pre-empt trade name conflicts by shifting decisions to earlier in the application process are still just getting off the ground. In one case, though, a company has taken matters into its own hands and is pressing the agency to make an early, public determination about whether a proposed brand name is acceptable
Drug Name Battles May Be Waged More Publicly; FDA Petitioned On Zentase
FDA's efforts to pre-empt trade name conflicts by shifting decisions to earlier in the application process are still just getting off the ground. In one case, though, a company has taken matters into its own hands and is pressing the agency to make an early, public determination about whether a proposed brand name is acceptable
Brand Names In 2008: Can Industry Pilot Its Way Out Of Trouble?
Industry may shoulder some of the burden of testing proprietary drug names this year under a pilot program included in the renewal of the Prescription Drug User Fee Act, but with that may come some clarity in a subjective field that so far has lacked detailed guidance from FDA